Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in <i><scp>KRAS</scp></i> wild‐type metastatic colorectal cancer patients: the ObservEr StudyCarmine Pinto, Francesco Di Costanzo, Antonio Frassoldati et al.|Cancer Medicine|2016Cited by 26
Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr studyGerardo Rosati, Francesco Di Costanzo, Carmine Pinto et al.|Journal of Geriatric Oncology|2018Cited by 13
Italian observational study in patients with metastatic colorectal cancer (mCRC) treated with first-line cetuximab based regimen (ObservEr study).Francesca Di Fabio, Carmine Pinto, Gerardo Rosati et al.|Journal of Clinical Oncology|2014Cited by 1
GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.Roberta Rudà, Riccardo Soffietti, Giuseppe Lombardi et al.|Journal of Clinical Oncology|2015Cited by 0
Prognostic factors in glioblastoma patients treated with the nitrosourea fotemustine at first relapse after the Stupp regimen: results from the GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology)Matteo Santoni, Roberta Rudà, Giuseppe Lombardi et al.|Annals of Oncology|2015Cited by 0